(Hong Kong, June 6, 2025) – Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, will lead a delegation of 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19, 2025. For the first time, Hong Kong’s two leading medical faculties—the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK)—will join the delegation. The goal is to showcase Hong Kong’s exceptional strengths and innovative potential in the life and health sciences on a global stage. By engaging with leading international tech pioneers, the delegation aims to attract enterprises, talent, and investors, thereby further enhancing Hong Kong’s status as a global biotech hub.
BIO 2025 brings together nearly 20,000 biotechnology industry leaders and professionals from approximately 70 countries and regions. The event covers comprehensive aspects of biotechnology, including research and development, clinical trials, manufacturing, business development, investment, and market commercialization.
Hong Kong has a strong foundation in scientific research and is home to world-class universities, which gives its life and health industry a competitive edge on the global stage. At the event, HKSTP will spotlight the remarkable research and innovations emerging from the park companies, highlighting Hong Kong’s advanced technological capabilities. Representatives from both medical faculties will also attend BIO to promote deeper engagement on this international platform. The participation will demonstrate Hong Kong’s remarkable achievements in the sector, attract business and investments opportunities, and further solidify Hong Kong’s role as a leading global biotechnology hub.
Professor Chak-sing Lau, Vice-President & Pro-Vice-Chancellor (Health) and Dean of Medicine at HKU, stated: “Health technology is a crucial pillar of Hong Kong's innovation landscape. HKUMed is dedicated to translating research into breakthroughs in drug development, vaccinology and stem cell biotechnology, in particular. From pioneering a nasal COVID-19 vaccine for emergency use to developing novel needle-free, live-attenuated influenza vaccines, and the first Hong Kong prescription oral arsenic-trioxide leukaemia drug for global use, we also play a key role in operating the Greater Bay Area International Clinical Trial Institute. These achievements reflect the relentless efforts of our Faculty in fostering innovation and collaboration with leading research institutions from the Mainland and around the world. Local universities and industry stakeholders are excelling in their respective fields, and we look forward to efficient collaboration among the Government, industry, academia, and the research and investment sectors to position Hong Kong as an international hub for health and medical innovation.”
Professor Philip Chiu, Dean of Medicine at CUHK, said, “We are devoted to promoting clinical translation of cutting-edge technologies. Our Faculty pioneers in the application of innovative non-invasive diagnostic methods, precision medicine in oncology, advanced gut microbiome technology and medical robotics to address health challenges such as an ageing population and emerging infectious diseases. Our innovations not only consolidate Hong Kong’s position as an international health and medical innovation hub but also provide solutions to some of the global health issues. We look forward to showcasing our latest research output and innovations to leaders of different backgrounds from around the world, attracting more international collaboration opportunities, and thereby enhancing Hong Kong’s international image as a hub for life sciences and health technology.”
Albert Wong, Chief Executive Officer of HKSTP, said: “We are delighted to showcase once again Hong Kong’s biotechnology expertise and potential at BIO 2025. The participation of esteemed representatives from our top medical faculties highlights the depth of our research capabilities and the collaborative spirit that is driving our growth as a biotech powerhouse. Hong Kong’s strategic positioning as a gateway between Mainland China and the international community enables us to actively support startups in exploring overseas business and investment opportunities while fostering ties with local innovation ecosystems. By attracting high-potential startups to establish a presence in Hong Kong, along with top-tier scientific talent and investment opportunities from around the world, we are solidifying Hong Kong’s position as an international innovation and technology hub.”
The delegation will participate in the 2025 Biomedical Pitch Competition on June 14, co-organized by the Boston Chinese Investment Club (BCIC) and supported by HKSTP. Three park companies advanced to the finals, competing for top honors. HKSTP also took part in this competition last year, where three participating companies successfully secured approximately HKD 80 million in investments.
The 16 Hong Kong companies attending BIO 2025 will showcase innovations spanning pharmaceuticals, gene editing, diagnostics, regenerative medicine, and more. These companies, supported by Incu-Bio Programme and Elite Programme of HKSTP, and the InnoHK initiative, highlight the remarkable range and depth of innovation thriving within Hong Kong’s biotech ecosystem.
Highlighted Innovations include:
- ARBELE – Pioneering innovative immunotherapies to address unmet clinical needs in gastrointestinal cancers.
- Beth Bioinformatics – Empowering vaccine developers with cutting-edge technologies such as virus evolution prediction (e.g. Influenza & SARS-CoV-2), epitope screening and codon optimization to co-develop high-efficacy, longer-lasting and novel vaccine products.
- Centre for Translational Stem Cell Biology (InnoHK) – Pioneering patented Expanded Potential Stem Cell (EPSC) technology to drive innovation in regenerative medicine, drug screening, precision medicine and therapeutic applications.
- DECODE CURE – Monitors and predicts trends in COVID-19, influenza, and urban antibiotic resistance through wastewater microbial data testing and analysis.
- GenEditBio – Specializes in developing in vivo genome editing therapies (referred to as "DNA surgery") by discovering novel Cas nucleases and creating safe, efficient in vivo delivery technologies to treat genetic mutation-related diseases.
- Immuno Cure – Completed of a first-in-human novel therapeutic HIV vaccine, ICVAX, Phase I clinical trial with encouraging findings of exceptional safety and promising immunogenicity profiles. Their Innovative Immunotherapy – DNA medicines and antibody immunotherapies for the treatment of infectious diseases, inflammation, and cancers.
The delegation aims to establish strategic partnerships, attract investment, facilitate technology transfer, and enhance international collaboration at BIO 2025 It will further strengthen Hong Kong’s role as a vibrant global biotechnology hub. Currently, Hong Kong Science Park is home to over 300 life and health technology companies. HKSTP provides comprehensive support, including incubation programmes, well-equipped laboratory facilities, and financial assistance to nurture startups and accelerate their commercialization.
Date: June 16-19, 2025
Location: Boston Convention & Exhibition Center (BCEC), USA
Booth: Exhibit Hall - 1751
For more details about BIO 2025, please visit: https://convention.bio.org/bio-2025
